Projects / Programmes
Early detection of Alzheimer’s disease with the novel biomarkers
| Code |
Science |
Field |
Subfield |
| 3.03.00 |
Medical sciences |
Neurobiology |
|
| Code |
Science |
Field |
| B640 |
Biomedical sciences |
Neurology, neuropsychology, neurophysiology |
| Code |
Science |
Field |
| 3.01 |
Medical and Health Sciences |
Basic medicine |
Alzheimer's disease, mild cognitive impairment, visual evoked potentials, magnetic resonance imaging
Researchers (13)
| no. |
Code |
Name and surname |
Research area |
Role |
Period |
No. of publicationsNo. of publications |
| 1. |
53026 |
Barbara Cussigh |
Neurobiology |
Technical associate |
2020 |
0 |
| 2. |
22466 |
PhD Irena Hren |
Public health (occupational safety) |
Researcher |
2019 - 2020 |
0 |
| 3. |
29860 |
PhD Voyko Kavcic |
Neurobiology |
Researcher |
2019 - 2023 |
0 |
| 4. |
38022 |
Katja Knez |
Public health (occupational safety) |
Technical associate |
2021 - 2023 |
0 |
| 5. |
52549 |
Sandra Martič |
Public health (occupational safety) |
Technical associate |
2021 - 2023 |
0 |
| 6. |
52123 |
PhD Marija Menih |
Neurobiology |
Researcher |
2019 - 2023 |
0 |
| 7. |
54152 |
Zdenka Milič Kavčič |
Public health (occupational safety) |
Researcher |
2020 - 2023 |
0 |
| 8. |
34093 |
Robert Pintarič |
Oncology |
Researcher |
2019 - 2023 |
0 |
| 9. |
28075 |
PhD Martin Rakuša |
Neurobiology |
Head |
2019 - 2023 |
0 |
| 10. |
52569 |
Sofia Rakuša |
Neurobiology |
Researcher |
2019 - 2023 |
0 |
| 11. |
52993 |
Aljaž Valič |
Sport |
Researcher |
2021 - 2023 |
0 |
| 12. |
52548 |
Karmen Vizjak Šterman |
Neurobiology |
Researcher |
2019 - 2023 |
0 |
| 13. |
25779 |
PhD Estera Žalik |
Psychiatry |
Researcher |
2020 - 2023 |
0 |
Organisations (2)
Abstract
Patients with a mild form of Alzheimer's disease (AD) or mild cognitive impairment (MCI) have grey and white matter (WM) impairments, which cause a collapse of the brain networks. This causes the delay of action potentials, which are demonstrated as cognitive decline in various cognitive areas. Among others, it includes disorders of motion detection and attention.
Impairment of WM can be non-invasively and objectively demonstrated. We may also find a correlation with the cognitive abilities of the patients. To assess the damage of WM MRI-DTI method can be used. Neurophysiological function of the brain network in visual-spatial and attention tasks can be assessed by visual evoked potentials evoked by motion onset (VEP-MO). Previous studies have used a separate approach. Patients either had MRI or have passed the neurophysiological testing.
Our approach will consist of a combination of standard neuropsychological testing, brain MRI and VEP-MO. In this way, we can find new non-invasive biomarkers that would indicate an impairment of cell structures (DTI imaging) and the functioning of the brain network (VEP-MO) in the processing of visual-spatial data and attention. New biomarkers would be included in the battery of tests for the early diagnosis of AD and will contribute to the successful treatment of AD.
Significance for science
With identification of the connections between cortical networks and their functioning, we will introduced at least two new biomarkers of early detection of AD at the international level.
Majority of research about the role of local cortical networks in visuospatial processing and attention have been restricted only to single patients group (MCI or AD). With investigation of the visuospatial functioning at patients transitioning from MCI to AD we will directly observe the role of separate fields, and in such way, we will obtain better data that will contribute to the understanding of cortical network functioning. These results could be used in the future.
Based on the results we will construct the battery of tests that will be adjusted to individual patient; with such adjustment, we will be able to reach AD diagnosis faster and with noninvasive methods that will enable us to provide better treatment.
Significance for the country
With identification of the connections between cortical networks and their functioning, we will introduced at least two new biomarkers of early detection of AD at the international level.
Majority of research about the role of local cortical networks in visuospatial processing and attention have been restricted only to single patients group (MCI or AD). With investigation of the visuospatial functioning at patients transitioning from MCI to AD we will directly observe the role of separate fields, and in such way, we will obtain better data that will contribute to the understanding of cortical network functioning. These results could be used in the future.
Based on the results we will construct the battery of tests that will be adjusted to individual patient; with such adjustment, we will be able to reach AD diagnosis faster and with noninvasive methods that will enable us to provide better treatment.
